RxDoctor Payments Data

Jeannette Aldous, MD

Internal Medicine · Encinitas, CANPI 1073650339

Payments from drug & device makers

$290,682in general payments, 2019–2025

Across 86 payments — averaging $3380.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biomerieux Inc$289K
  • Viiv Healthcare Company$1K
  • Gilead$287
  • Johnson & Johnson$82
  • GSK$21
  • Theratechnologies Inc.$20

What the payments were for

  • Food & beverage$1,69096%
  • Education$774%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Biomerieux Inc16$288,915
Viiv Healthcare Company54$1,357
Gilead10$287
Johnson & Johnson(2 entities)4$82
GSK1$21
Theratechnologies Inc.1$20

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$290,682 in reported general payments places this provider in the 95th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$767
Medicare patients
17
Services billed
41

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
DovatoDolutegravir Sodium/Lamivudine164$461,646
BiktarvyBictegrav/Emtricit/Tenofov Ala112$440,394
OdefseyEmtricitab/Rilpiviri/Tenof Ala53$182,209
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf29$135,038
TivicayDolutegravir Sodium62$133,248
StribildElviteg/Cob/Emtri/Tenofo Disop11$44,876
GenvoyaElviteg/Cob/Emtri/Tenof Alafen12$42,510
JulucaDolutegravir/Rilpivirine13$40,375
PrezcobixDarunavir/Cobicistat11$26,002
OzempicSemaglutide19$20,883
EvotazAtazanavir Sulfate/Cobicistat13$19,799
Maraviroc12$16,568
LyricaPregabalin12$14,241
JanuviaSitagliptin Phosphate24$12,749
JardianceEmpagliflozin18$12,406

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Viiv Healthcare CompanyDovato, Tivicay, Juluca$1,357$635,268239 claims
GileadBiktarvy, Stribild, Genvoya$287$527,780135 claims
Johnson & JohnsonPrezcobix$82$26,00211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Encinitas

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →